Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAaron D. SchimmerKYKaren YeeHSHassan Sibai

Discussion

Loading...

Member takes

Overview

Observational analysis shows MFC-MRD status predicts relapse-free survival in FLT3-ITD acute myeloid leukemia, indicating prognostic value amidst mutations.

Key Points

  • MFC-MRD negativity improves relapse-free survival in patients with FLT3-ITD AML, along with DNMT3A-related outcomes.
  • Two-year overall survival was recorded at 55.6%, with the 2-year relapse-free survival at 57.1% for both MFC-MRD status groups.
  • Kaplan-Meier method and Cox proportional hazard models were utilized to analyze overall and relapse-free survival outcomes.
  • Further exploration is needed to evaluate the prognostic impact of MFC-MRD in specific mutation subgroups for acute myeloid leukemia.

Cite This Study

Schimmer et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c9https://doi.org/10.1182/blood-2025-7051
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  2. 2Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  3. 3Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025
  4. 4The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.2025
  5. 5Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)2025 · 1 citations